Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $191
Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
NBIX or GRDN: Which Is the Better Value Stock Right Now?
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice
All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy
NBIX vs. GRDN: Which Stock Is the Better Value Option?
Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?
Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences Releases Findings From New Survey Showing Adults With Tardive Dyskinesia Reported Fewer Disruptions To Work, School After Starting Treatment With INGREZZA Capsules
Neurocrine Biosciences: Breaking Down A Solid Quarter
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224
Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation
Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost Free
Neurocrine Biosciences, Inc. 2026 Q3 - Results - Earnings Call Presentation
Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress
Is Neurocrine Biosciences (NBIX) A Bargain On Raised INGREZZA Guidance?
Neurocrine Biosciences (NBIX) Starts Phase 2 Alzheimer’s Study And Expands Doctor Education
Neurocrine Biosciences (NBIX) Stock Looks Cheap After Its 55% Five Year Run
This Biopharma Stock Hit a 6-Year High—and It Can Keep Climbing
Neurocrine Biosciences Delivers Strong Q3 on Vykat Rebound, RBC Says
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.